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Abstract
The Fip1-like1 (FIP1L1)-platelet-derived growth factor receptor alpha fusion gene (F/P) arising in the pluripotent
hematopoietic stem cell (HSC),causes 14% to 60% of patients with hypereosinophilia syndrome (HES). These patients,
classified as having F/P (+) chronic eosinophilic leukemia (CEL), present with clonal eosinophilia and display a more
aggressive disease phenotype than patients with F/P (–) HES patients. The mechanisms underlying predominant eosinophil
lineage targeting and the cytotoxicity of eosinophils in this leukemia remain unclear. Given that the Janus tyrosine kinase
(JAK)/signal transducers and activators of transcription (Stat) signaling pathway is key to cytokine receptor-mediated
eosinophil development and activated Stat3 and Stat5 regulate the expression of genes involved in F/P malignant
transformation, we investigated whether and how JAK proteins were involved in the pathogenesis of F/P-induced CEL. F/P
activation of JAK2, Stat3 and Stat5, were confirmed in all the 11 F/P (+) CEL patients examined. In vitro inhibition of JAK2 in
EOL-1, primary F/P(+) CEL cells (PC) and T674I F/P Imatinib resistant cells(IR) by either JAK2-specific short interfering RNA
(siRNA) or the tryphostin derivative AG490(AG490), significantly reduced cellular proliferation and induced cellular
apoptosis. The F/P can enhance the IL-5-induced JAK2 activation, and further results indicated that JAK2 inhibition blocked
IL-5-induced cellular migration and activation of the EOL-1 and PC cells in vitro. F/P-stimulation of the JAK2 suppressed cells
led to a significantly reduction in Stat3 activation, but relatively normal induction of Stat5 activation. Interestingly, JAK2
inhibition also reduced PI3K, Akt and NF-kB activity in a dose-dependent manner, and suppressed expression levels of c-Myc
and Survivin. These results strongly suggest that JAK2 is activated by F/P and is required for F/P stimulation of cellular
proliferation and infiltration, possibly through induction of c-Myc and Survivin expression via activation of multiple signaling
pathways, including NF-kB, Stat3, and PI3K/Akt.
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Introduction
An interstitial deletion on chromosome 4q12 results in the
formation of the Fip1-like1 (FIP1L1)-platelet-derived growth
factor receptor alpha fusion gene (F/P), which triggers the
occurrence of chronic eosinophilic leukemia (CEL) [1]. F/P(+)
CEL is characterized by hyperproliferation of clonal eosinophils
and life-threatening organ damage, especially affecting the lungs
and/or the heart, due to eosinophil degranulation of toxic
mediators [2]. The F/P fusion protein acts as a constitutive
activator of the transmembrane receptor protein-PDGFRA [3,4],
which activates several signal molecules such as PI3K, MEK,
JNK, ERK1/2 and the Stats [5,6,7]. However, to date, it remains
largely unknown which intracellular activated pathways and
critical signal molecules underlie the F/P-mediated malignant
phenotype of CEL.
Some studies on F/P(+) CEL have provided insights into the
molecules that may contribute to this disease. A recent
comparative proteomic analysis of eosinophils from F/P(+)
patients, non-clonal hypereosinophilia syndrome (HES) patients
and healthy donors indicated that SHP-1 tyrosine phosphatase
activity was distinctively up-regulated in F/P(+) cells [8]. Another
study investigating the effects of the pharmacological protein-
tyrosine kinase inhibitor dasatinib found that the Lyn protein was
excessively activated in F/P(+) CEL [9]. Since the pathogenesis of
F/P(+) eosinophilia-associated atypical myeloproliferative neo-
plasms (Eos-MPN) is similar to that of BCR-Abl(+) chronic
myeloid leukemia (CML), the involved signaling mechanisms may
also be similar. Both diseases constitute a paradigmatic example of
how constitutively active tyrosine kinases drive chronic leukemo-
genesis. JAK2 plays a vital role in the signal network mediating
BCR-Abl(+) CML [10]. Recent results have indicated that JAK2,
a downstream target of BCR-Abl, can maintain activated Lyn
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mediate the BCR-Abl-induced activation of Lyn and SHP-1
kinase [11].
F/P induction of c-Myc promotes EOL-1 cellular proliferation,
and the anti-apoptosis activity of F/P in eosinophils may be
associated with high expression levels of cellular Survivin [7,12].
Nonetheless, the mechanism by which F/P regulates c-Myc and
Survivin is unknown. JAKs are cytoplasmic tyrosine kinases that
participate in signaling initiated by a range of cell-surface
receptors, including PDGFRA and a number of cytokine receptor
superfamily members [13]. Eosinophil development during
normal hematopoiesis occurs via the JAKs/Stats pathway [14],
and c-Myc is a key target gene of JAKs during cytokine IL-5-
induced eosinophil processes [15]. F/P has been shown in a mouse
CEL model to cooperate with IL-5-dependent signaling to drive
abnormal eosinophil infiltration and activation [16]. JAKs have
also been shown to play a vital role in IL-5-dependent eosinophil
migration and activation during the inflammatory reaction [17].
However, the role of JAKs in IL-5-induced chemotaxis and
activation of EOL-1 cells has yet to be determined.
In this study, we initially examined whether JAK2 was involved
in the F/P signaling pathway driving leukemia formation and
whether it was stimulated by F/P synergistic with IL-5. Then, we
investigated whether JAKs mediated the F/P-induced expression
of c-Myc and Survivin. Finally, we investigated which JAKs-
related signal transduction pathways, and particular downstream
signal molecules, were aberrantly regulated in F/P(+) EOL-1 cells.
The results indicate that JAK2 kinase is activated by F/P, and is
required for F/P stimulation of cellular proliferation and
infiltration by modulation of activities or expressions of multiple
intracellular/nuclear molecules.
Materials and Methods
The present study protocol was approved by the ethical
committee at Xiangya Hospital of Central South University,
Changsha, China.
Patient Samples
A total of 28 patients, including 23 cases of HES, five of reactive
eosinophilia (RE, two of which were eosinophilic gastroenteritis
and three were ancylostomiasis) and five healthy volunteers, were
included in this study. Karyotype analysis was normal. No
abnormal chromatosomes, including those of PDGFRB, FGFR1
and JAK2, were detected in any of the cases [18]. The 23 HES
patients met all the criteria for the diagnosis of HES, as proposed
by Chusid [19]. Nested RT-PCR and fluorescence in situ
hybridization (FISH) analyses were performed on all samples,
and the F/P fusion gene was detected in the 11 HES/CEL
patients, but not in the other 12 HES patients or other subjects. 10
of the 11 F/P(+) CEL cases had organ involvement (three of which
had one affected organ and seven had at least two affected organs).
Eosinophilic organ involvement/dysfunction comprised the spleen
(n=7), heart (n=6), lung (n=3), liver (n=3), and the central
nervous system (n=1). The concentrations of serum IgE and IL-5
were normal in all 11 F/P(+) CEL patients. All these F/P(+) CEL
patients had been treated with Imatinib, at initial daily doses
ranging from 100 to 400 mg. All Imatinib-treated patients
achieved complete haematological remission (CHR) (range:3–60
days), and ten of 11 patients with the F/P gene exhibited
molecular remission (MR) within 1–19 months post-treatment
(one patient was lost to follow-up). After obtaining informed
consent, blood and bone marrow samples were collected from
HES/CEL patients at the time of diagnosis at the Xiangya
Hospital of Changsha.
Cell Culture and Treatment
EOL-1 cells carried the WT F/P fusion oncogene (Braunsch-
weig, Germany) [20]. Ba/F3 cells expressing T674I F/P resistant
to Imatinib (IR) have been described previously [1]. After
obtaining blood from the above-mentioned patients, polymorpho-
nuclear leucocytes were separated by standard laboratory
procedures [21]. Eosinophils were then separated by depletion
of neutrophils with anti-CD16-coated magnetic microbeads using
the magnetic cell separation system (MACS; Miltenyi Biotec
GmbH, Bergisch- Gladbach, Germany) according to the following
method(http://www.miltenyibiotec.com/download/datasheets_en
/23/DS130_045_701.pdf). Eosinophils of greater than 95% purity
were used in all functional experiments. All these cell lines and
primary cells were maintained in RPMI-1640 medium supple-
mented with 10% fetal bovine serum (FBS) (Hyclone, USA) at 37uC
in a humidified atmosphere of 5% CO2. The EOL-1 cells were
treated with various concentrations of Imatinib mesylate (Gleevec,
Novartis Switzerland) as indicated [1]. To determine the concen-
tration of AG490 necessary to achieve maximal effects on JAK2
protein expression, a dilution series of AG490 in DMSO was
prepared and applied to EOL-1 cells. An equal volume of DMSO
was added to control wells. The results showed that 25 mM AG490
achieved ,50% inhibition of JAK2 expression within 4 h, and
100 mM AG490 gave maximal inhibition (data not shown).
According to these result, cells were selected to undergo JAK2
inhibition using different concentrations of AG490.
Stimulation of Cells with IL-5
To determine whether synergism between the F/P and IL-5 to
induces JAK2 kinase activation in human eosinophils. EOL-1 or
primary F/P(+) CEL cells (PC) (5610
5/mL) were preincubated
with or without Imatinib (10 nM) for 4 h and stimulated with IL-5
(5 ng/mL at 37uC for 0 to 5 min). The phosphylation level of
JAK2 was detected by Western blot at the time points of 0, 2 and
5 min after IL-5 stimulation.
Silencing of JAK2 Expression
EOL-1, PC and T674I F/P Imatinib-resistant (IR)cells were
incubated with 1610
22 mM of human JAK2 siRNA (Accell
SMARTpool E-003146-00-0005, Thermo Fisher Scientific, Wal-
tham, MA, USA) for 48 h, JAK2 mRNA and protein levels were
measured using the RT-PCR and immunoblotting assays
described above. A non-targeting scrambled siRNA (Accell Non-
targeting pool D-001910-10-05, Thermo Fisher Scientific, Wal-
tham, MA, USA) was used as a control in each sample.
Cellular Proliferation and Apoptosis Assay
The cellular proliferation assay was performed using 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT).
Briefly, EOL-1, PC and IR cells were resuspended in RPMI-1640
medium (1.25610
5/mL) and dispensed into 96-well culture plates
in 200 ml volumes. The cells were cultured and treated with either
JAK2 inhibitor (AG490) or JAK2 siRNA as described above. At
the end of the incubation, the cells were washed with PBS buffer
and 50 ml of the MTT solution was added to each well. The plates
were incubated for 4 h at 37uC and 5% CO2. The MTT solution
was then removed and 150 ml of DMSO was added to each well.
Finally, the absorbance (A value) was measured using a micro-
culture plate reader at 490 nm. The cellular proliferation
inhibition rate by AG490 or JAK2 siRNA was calculated
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bance value of blank control group at 490 nm) – (absorbance value
of the treated group at 490 nm)/absorbance value of blank control
group at 490 nm]6100%. Apoptosis was determined by Annexin-
V-FLUOS and propidium iodide(PI) double staining. The cell
cycle was determined by propidium iodide nuclear staining
according to the manufacturers’ instructions (BD Biosciences
Pharmingen, USA). Briefly, EOL-1, PC and IR cells were cultured
and treated with either JAK2 inhibitor (AG490) at 0 mM, 25 mM,
75 mM, and 100 mM or JAK2 siRNA as described above. At the
end of incubation, 1–10610
5 cells/mL were harvested, washed
with PBS, and fixed with 70% ethanol. After incubation with
propidium iodide for 30 min at 37uC, the cells were analyzed
using a FACS Calibur flow cytometer (BD Biosciences). Data were
collected and analyzed by the accompanying BD CellQuest
software.
Preparation of Nuclear Extracts
Cells were washed twice in 1 mL ice-cold PBS, resuspended in
400 mL hypotonic lysis buffer containing protease inhibitors, and
incubated on ice for 20 min. Then, 12.5 mL of 10% NP-40 was
added and the cell suspension was vigorously mixed for
15 seconds. The extracts were centrifuged for 2 min and the
supernatants (cytoplasmic extracts) were discarded. Ice-cold
nuclear extraction buffer (25 mL) was added to the pellets and
incubated for 30 min with intermittent mixing. Extracts were
centrifuged and the supernatant (nuclear extracts) transferred to
pre-chilled tubes for storage at 270uC.
Immunoprecipitation and Immunoblotting
Cells were rinsed twice with ice-cold PBS, solubilized in lysis
buffer (50 mM Tris, pH 7.5, 1% NP-40, 150 mM NaCl, 2 mM
EGTA, 1 mM Na3VO4, 100 mM NaF, 10 mM Na4P2O7,
1 mM phenylmethylsulfonyl fluoride, 10 mg/mL aprotinin,
10 mg/mL leupeptin), and centrifuged at 140006g for 10 min at
4uC. The supernatant (cell extracts) was incubated on ice with
anti-PDGFRA antibody (1:1000 dilutions; Santa Cruz Biotech-
nology, USA) for 2 h. The immune complexes were collected
following incubating with protein A-agarose (Roche, USA) at 4uC
for 1 h. The beads were then washed three times with washing
buffer (50 mM Tris, pH 7.5, 1% NP-40, 150 mM NaCl, 2 mM
EGTA) and boiled for 5 min in SDS-PAGE sample buffer
(50 mM Tris-HCl, pH 6.8, 2% SDS, 2% mercaptoethanol, 10%
glycerol, 0.005% bromphenol blue). The solubilized proteins were
separated by SDS-PAGE, transferred to a nitrocellulose mem-
brane (Amersham Biosciences, Sweden), and detected by immu-
noblotting against phosphotyrosine (4G10) antibody. Whole-cell
lysates were prepared from the cells, and western blotting was
performed as described previously [22]. Blots were probed with
the primary antibodies against phospho-JAK3(Tyr980)(p-JAK3),
JAK3, phospho-Stat3(p-Stat3), Stat3, phospho-Stat5b(p-Stat5b),
Stat5b, c-Myc, phospho-p85a(PI3K)/(Tyr467)(p-p85a), p85a,
phospho-Akt1(Thr308/Ser473)(p-Akt1) and Akt1(1:100–1:2000
dilutions; Santa Cruz Biotechnology); phospho-Stat3(Tyr705)(p-
Stat3), phospho-Stat5(Tyr694)(p-Stat5), phospho-JAK1 (pTyr
1022/1023)(p-JAK1), JAK1, phospho-JAK2 (Tyr1007/1008)(p-
JAK2), JAK2, Survivin and b-actin (1:1000–1:2000 dilutions; Cell
Signaling Technology, USA) followed by incubation with the
secondary antibodies were used peroxidase- conjugated goat anti-
mouse IgG or goat anti-rabbit IgG (1:4000–1:5000; Jackson
ImmunoResearch Inc., USA) and enhanced chemiluminescent
substrate. Nuclear extracts (500 ng protein per lane) were probed
for phospho-p65 by Western blotting using antibodies to phospho-
(NF-kB) p65/(Ser-536)(p-p65) (1:100–1:2000 dilutions; Cell Tech-
nology, USA) and PARP (control). Densitometry analysis was
performed on exposed films using Quantity One v4.62 software
(Bio-Rad, USA).
Eosinophil migration and function Assay
The migration properties of EOL-1 and PC cells were analyzed
in a 48-well microchamber (Neuroprobe, USA), in which the
lower wells were filled with 28 mL of buffer alone or buffer
containing 5 ng/mL IL-5. A fibronectin-coated polyvinylpyrroli-
done-free filter (Neuroprobe) with 5 mm pores was placed over the
lower wells and 50 mL of EOL-1 or PC cells at 4610
6 cells/mL
was added to the upper wells. The chamber was incubated for 2 h
at 37uCi naC O 2 incubator. The polycarbonate filter was then
removed and cells adhering to the upper surface were wiped off
using a filter wiper. The filter was dried, fixed, and stained with
Diff-Quick reagent (Baxter Diagnostics, USA). The cells in two
randomly selected fields per well were counted using the Axiovert
25 microscope (Carl Zeiss, Germany). Each experiment included
six replicate measurements. The chemotactic index (CI) was
calculated as the number of cells that migrated in the experimental
wells compared to those in control wells(which was set at 100%).
EPO activities in EOL-1 and PC cells were measured using the
following method. Briefly, 1610
6 cells/mL were plated on 6-well
plates and incubated for 30 min in the presence of 5 ng/mL IL-5.
EPO activity in EOL-1 or PC cells was measured by an enzyme-
joint spectrophotometer, using the optical density (OD) value at an
absorbance of 492 nm. The degranulation of EOL-1 or PC cells
was detected using 180 mL of the 1610
6 cells/mL suspension in an
Eppendorf tube. Following an initial incubation of 24 h at 37uC,
IL-5 was added and the solution incubated for an additional
30 min, after which cells were collected by centrifugation (50006g
at 20uC for 5 min), washed with phosphate buffered saline (PBS),
and resuspended in 200 mL Hank’s salt solution. The cells were
lysed by ultrasonication for 5 min, and the EPO activity was
measured according Strath’s method [23].
Statistical Analysis
Data are presented as mean 6standard deviation (SD). Data
were compared using the two-way analysis of variance(ANOVA)
test or independent sample t test. P values less than 0.05 was
considered statistically significant and were derived from 2-tailed
statistical test. All statistical treatment was performed using SPSS
13.0 software.
Results
Excessive phosphorylation of JAK2, Stat3 and Stat5 in F/
P(+) CEL patients
The 23 HES patients included 20 males and three females with
a median age at diagnosis of 43 years (range: 15–73). The median
white blood cell (WBC) count was 20.3610
9/L (range: 5–97) with
an absolute eosinophil count (AEC) of 9.7610
9/L (range: 2.0–39).
Serum IgE and IL-5 were within the normal range. The five RE
patients had an AEC of 2.6610
9/L (range: 1.0–5.0), while the five
healthy volunteers had an AEC of 0.2610
9/L (range: 0–0.5).
JAK2, Stat3 and Stat5 are closely related to the differentiation
and proliferation of eosinophils. To determine whether these
proteins were differentially activated in F/P(+) CEL patients,
polymorphonuclear leucocytes and eosinophils were collected
from all subjects and immunoblotted. Western blot results showed
that phosphorylated JAK2 proteins were present at higher levels in
F/P(+) CEL patients than in other eosinophilia patients lacking the
F/P fusion gene or healthy volunteers (Figure 1A, B). The
phosphorylated forms of Stat3 and Stat5 were also significantly
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(Figure 1A, C). However, total JAK2, Stat3 and Stat5 expression
was not different among the groups. As expected immunoprecip-
itation of cell extracts with anti-PDGFRA antibody followed by
immunoblotting with anti-phosphotyrosine (4G10), showed that
phosphorylated F/P proteins were only detected in the 11 F/P(+)
CEL patients (Figure 1A, D). Taken together these results indicate
that F/P(+) CEL is uniquely characterized by excessive phosphor-
ylation of JAK2, Stat3, and Stat5.
Treatment of F/P(+) CEL patients and EOL-1 cells with
Imatinib down-regulates phosphorylation of JAK2, Stat3
and Stat5 in a time- and dose-dependent manner
The drug of choice for patients diagnosed with F/P(+) CEL is
Imatinib, a specific inhibitor of F/P which often results in
complete remission. All the 11 F/P(+) CEL patients in our study
were also treated with Imatinib. Complete clinical remission was
evidenced by abatement or disappearance of symptoms and/or
changed laboratory values from the involved organ. To investigate
whether phosphorylation of JAK2, Stat3, and Stat5 proteins were
inhibited in F/P(+) CEL after treatment with Imatinib, peripheral
blood samples were obtained at four different time-points: pre-
therapy (day 0), post-therapy day 10 and day 30, and at the time of
MR. In addition, we treated cultured EOL-1 cells with various
concentrations of Imatinib. The results showed that the phos-
phorylation levels of JAK2, Stat3, and Stat5 were significantly
decreased in both F/P(+) CEL patients and EOL-1 cells after
treatment with Imatinib. The down-regulated phosphorylation
levels of JAK2, Stat3, and Stat5 were correlated with the reduction
in phosphorylation of the F/P in a time- and dose-dependent
manner following Imatinib treatment (Figure 2, 3). These findings
indicate that JAK2, Stat3, and Stat5 proteins lie downstream of
the F/P signal.
Figure 1. Activation of JAK2, Stat3 and Stat5 molecules in F/P (+) CEL patients. Cell extracts were prepared from blood samples of the cases
with (F/P (+): F/P (+) CEL, F/P (2): F/P (2) HES, RE: reactive eosinophilia, and healthy volunteers) and subjected to western blotting or
immunoprecipitation (IP). (A) Gel images of representative gel images. (B–D) Quantification of A. The results represent mean6SD of the cases(F/P (+)
CEL [n=11], F/P (2) HES [n=12], RE [n=5], and healthy volunteers [n=5]). *P,0.05, compared to the other groups.
doi:10.1371/journal.pone.0034912.g001
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primary F/P(+) CEL cells (PC) and T674I F/P Imatinib-
resistant cells(IR)
The F/P oncoprotein is known to induce cellular proliferation
and regulate prolonged survival of eosinophils. To explore
whether the phosphorylation of JAK2 also contributes to cellular
proliferation, we inhibited JAK2 activation with the specific
inhibitor, AG490, or JAK2 siRNA and assessed the cellular
growth using MTT assay (Figure 4). The results showed that the
cellular proliferation inhibitory rate gradually increased with
increasing AG490 concentration in EOL-1 cells. A similar result
was also obtained with JAk2 knock-down (Figure 4B, E). We also
observed that JAK2 inhibition or knock-down suppressed cellular
proliferation in PC cells from patients (Figure 4C, E). More
importantly, we found that cellular growth in IR cells was
obviously repressed by JAK2 inhibition or knock-down (Figure 4D,
E), indicating that a JAK2 inhibitor, to a certain extent, may
represent an effective alternative therapy in Imatinib-resistant
CEL.
JAK2 inhibition induces cellular apoptosis of EOL-1, PC
and IR cells
The delay in apoptosis delay of eosinophils is another
characteristic of F/P-mediated CEL. Therefore, we explored the
role of JAK2 in delayed cellular apoptosis in F/P(+) CEL using the
FACS assay. The results showed that EOL-1 cells underwent
significant spontaneous apoptosis following exposure to the JAK2
kinase inhibitor, AG490, or transfection with JAK2 siRNA
(Figure 5A, B, C). Similar results were also obtained in PC
(Figure 5A, B, D) and IR cells (Figure 5A, B, E). These results
indicated that the survival of F/P-mediated CEL cells was
associated with activation of JAK2.
Figure 2. Inhibition of F/P tyrosine kinase by imatinib in CEL patients decreased phosphorylation of JAK2, Stat3 and Stat5 in a
time-dependent manner. Blood samples were obtained from the F/P(+) CEL patients (n=3) at pre-therapy (day 0), day 10, day 30 after therapy
and at the time of molecular remission (M.R.). Eosinophils were separated by depletion of neutrophils with anti-CD16-coated magnetic microbeads
using the magnetic cell separation system and whole-cell lysates were subjected to western blotting or immunoprecipitation (IP). (A) Gel images of
representative gel images. (B–D) Quantification of A. Data (mean6SD) representative results derived from three independent experiments. *P,0.05,
compared to day 0.
doi:10.1371/journal.pone.0034912.g002
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Our results suggest that JAK2 lies downstream of the F/P fusion
protein. JAK2 is a known downstream effector of IL-5-stimulated
signaling, which is implicated in the development, migration and
activation of eosinophils. Therefore, we investigated whether the
synergism between F/P and IL-5 to induced JAK2 activation
using Western blotting. As expected, the results showed that IL-5
induced JAK2 activation in EOL-1 and PC cells, however, JAK2
activation was significantly inhibited by Imatinib, a specific
inhibitor of the F/P (Figure 6), indicating a synergistic stimulation
of JAK2 activation by F/P and IL-5 in these cells.
JAK2 inhibition blocks IL-5-induced cellular migration
and activation of EOL-1, PC and IR cells in vitro
Introduction of the F/P fusion gene to CD34+ hematopoietic
stem cells(HSCs) induces myeloid proliferation and primes
eosinophil differentiation, however, the development of eosino-
phil-associated end-organ infiltration and damage requires
additional cytokines, especially robust expression of IL-5.
Western blot results have showed that JAK2 was excessively
activated by the F/P synergistic between and IL-5 (Figure 6). To
explore the role of JAK2 in the migration and activation of EOL-
1 and PC cells, IL-5 was applied as a chemoattractant and the
effects of JAK2 inhibitor or knock-down were assessed. The
results showed that JAK2 inhibition significantly blocked cells
migration (Figure 7A, D) and depressed IL-5-induced cellular
EPO activity (Figure 7B, E) and cell degranulation (Figure 7C, F)
in a dose-dependent manner. These results indicate that
activation of JAK2 enhances the invasive power of eosinophils,
and maybe also be focus of F/P and IL-5 acting together in a
synergistic manner to promote development of the CEL-like
phenotype.
Figure 3. The specific F/P inhibitor imatinib down-regulated the phosphorylation level of JAK2, Stat3 and Stat5 in a dose-
dependent manner. EOL-1 cells were treated with various concentrations of Imatinib. Whole-cell lysates were prepared and subjected to western
blotting or immunoprecipitation. (A) Representative gel images. (B–D) Quantification of A. Data(mean6SD) representative results derived from three
independent experiments. *P,0.05, compared to the untreated group.
doi:10.1371/journal.pone.0034912.g003
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Stat3 and the PI3K/Akt signaling pathway in EOL-1 cells
The above data demonstrate that JAK2 kinase was essential for
F/P-induced CEL cellular proliferation, survival and activation.
We next investigated which signal transduction pathways
involving JAK2 were disrupted in F/P(+) EOL-1 cells. These cells
were treated with different concentrations of AG490 and
evaluated by western blot with antibodies to the various molecules
related to JAK2 (Figure 8A, B). Phosphorylation of Stat3 was
found to decrease gradually with increased AG490 concentration.
The phosphorylation status of Stat5 showed no obvious changes at
low AG490 concentrations, but showed a slight decrease in the
phosphorylated form at high concentration (100 mmol/L)
(Figure 8A, C). JAK2 inhibition by AG490 also caused a dramatic
and dose-dependent decrease in the phosphorylation level of PI3K
and Akt (Figure 8A, D). To confirm these findings, we examined
the effects of JAK2 knock-down by JAK2 siRNA in EOL-1 cells.
Phosphorylation of Stat3, PI3K and Akt were considerably
reduced in JAK2 knock-down cells, as compared with non-
silenced cells (Figure 8A, C, D). In contrast, JAK2 knock-down
Figure 4. JAK2 inhibition or knock-down by AG490 or transfection of JAK2 siRNA significantly inhibited cellular proliferation in
EOL-1, primary F/P(+) cells (PC) and T674I F/P Imatinib-resistant cells (IR). Cells were treated with various concentrations of AG490 or
transfected with JAK2 siRNA. (A) Knock-down of JAK2 expression was confirmed by RT-PCR. (B–E) JAK2 inhibition or knock-down decreased cellular
proliferation as assessed by MTT assay. Data(mean6SD) representative results derived from three independent experiments. *P,0.05, compared to
untreated group or control siRNA.
doi:10.1371/journal.pone.0034912.g004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34912Figure 5. JAK2 inhibition or knock-down by AG490 or transfection of JAK2 siRNA induced cellular apoptosis in EOL-1, PC and IR
cells. Cells were treated with various concentrations of AG490 or transfected with JAK2 siRNA. JAK2 inhibition increased cellular apoptosis assessed
by flow cytometry using Annexin-V and PI. (A–B) Representative flow cytometry patterns. (C–E) Percentages of apoptotic cells treated with various
concentrations of AG490 or transfected with JAK2 siRNA. Data(mean6SD) representative results derived from three independent experiments.
*P,0.05, as compared to the untreated group or control siRNA.
doi:10.1371/journal.pone.0034912.g005
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These results indicate that JAK2 can mediate the F/P-induced
activation of Stat3 and the PI3K/Akt pathway, but is not the
principal mediator of F/P-induced Stat5 activation.
Inhibition of JAK2 downregulates the expression of
multiple target genes including NF-kB, c-Myc and
Survivin in EOL-1 cells
NF-kB is believed to play a role in the migration and activation
of eosinophils. To examine the effect of JAK2 on NF-kB activity
and further assess the role of JAK2 in the F/P-induced expression
of c-Myc and Survivin, EOL-1 cells were treated with various
concentrations of the JAK2 inhibitor AG490 and immunoblotted.
The nuclear fractions were assessed for the phosphorylation level
of the NF-kB p65 subunit and the whole protein extracts were
assessed for c-Myc or Survivin. The results showed that p65
phosphorylation in the nuclear fraction, and c-Myc and Survivin
expression in the whole cell were dramatically decreased by JAK2
inhibition in a dose-dependent manner. JAK2-siRNA transfected
EOL-1 cells also showed significant reduction in the expression of
the above genes, as compared with the non-silenced controls
(Figure 8A, B, E). These results indicate that c-Myc and Survivin
are both downstream targets of JAK2, and that JAK2 has an
important role in maintaining NF-kB sustained activity in F/P(+)
eosinophils.
Discussion
The F/P fusion protein, acting as a constitutively active tyrosine
kinase, triggers a series of intracellular molecular events leading to
the occurrence of CEL. The mechanisms underlying the
predominant eosinophil lineage targeting and eosinophil cytotox-
icity in this leukemia remain unclear. In this study, we have shown
for the first time that JAK2 is involved in the F/P-stimulation of
cellular proliferation and infiltration via multiple signaling
pathways. Several lines of evidence support this conclusion. First,
by evaluating the effects of the specific inhibitor Imatinib in vivo and
in vitro, we demonstrated that JAK2, as well as Stat3 and Stat5, are
downstreams of the F/P fusion gene. Second, JAK2 inhibition by
AG490 or siRNA dramatically inhibited cellular proliferation and
induced cellular apoptosis of the EOL-1, primary F/P(+) CEL
(PC) and T674I F/P Imatinib-resistant CEL (IR) cells. Third,
JAK2 kinase was the synergized downstream of the F/P and IL-5,
and JAK2 inhibition significantly blocked IL-5-induced cellular
migration and activation of EOL-1 and PC cells. Fourth, specific
inhibition of JAK2 significantly suppressed the phosphorylation of
Stat3, but had no obvious effect on the phosphorylation level of
Stat5. Finally, JAK2 inhibition led to a dose-dependent decreases
in PI3K, Akt and NF-kB activity and reduced F/P-induced
expressions of c-Myc and Survivin.
JAK proteins are central components of hematopoietic cell
production and biological function, and effective targets of
myeloproliferative neoplasms [24,25]. A recent study showed that
JAKs induction of c-Myc is critical to IL-5 stimulation of
eosinophil cell proliferation and inhibition of apoptosis [15]. Our
study showed that all 11 CEL patients carrying the F/P gene
exhibited more intense phosphorylation of JAK2 than the other
eosinophilia cases without this fusion gene. There were no
statistical differences in the expressions of phospho-JAK1 or
phospho-JAK3 (data not shown). Phosphorylation of JAK2 was
inhibited by Imatinib in a time- and dose-dependent manner.
Collectively, these findings suggest that JAK2, and not JAK1 or
Figure 6. The synergistic role of F/P and IL-5 in inducing JAK2 activation in EOL-1 and PC cells. The EOL-1 or PC cells were preincubated
with or without Imatinib for 4 h followed by treatment with 5 ng/mL IL-5 for 0 to 5 min. Whole-cell lysates were prepared and subjected to western
blotting. (A) Representative gel images. (B–C) Quantification of A. Data(mean6SD) representative results derived from three independent
experiments. * P,0.05, as compared to 0 minute. # P,0.05, compared to the differences between the Imatinib treatment and non-treatment for all
the doses.
doi:10.1371/journal.pone.0034912.g006
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ingly, eosinophilic gastroenteritis patients express high levels of
phospho-JAK3, which is coincident with the finding that JAK3
activation is critical for airway eosinophilic inflammation, as in
asthma and rhinitis [26]. In addition, the F/P-induced activation
of Stat3 and Stat5 observed in our study was consistent with
previous findings [1,5,27,28].
EOL-1 cells harbor the F/P fusion gene, which inhibits
eosinophilic precursor cells from differentiating into mature
eosinophils, but also causes transformation into leukemia cells
[20]. F/P-transformed cells have been demonstrated to undergo
cytokine-independent proliferation. One of the major mechanisms
of F/P(+) CEL malignancy is the up-regulation of c-Myc induced
by F/P [7]. The F/P oncoprotein has also been implicated in the
prolonged survival of eosinophils in CEL [7,29], which may result
from the abnormally high expressions of c-IAP and Survivin [12].
However, the molecular process by which the F/P signal elicits
rapid changes in gene expression in eosinophils is not well
understood. Multiple signal molecules, including Stats, PI3K, and
ERK1/2 proteins, have been shown to be important, but not
sufficient for mediating the F/P oncogenic transformation function
[5]. In the present study, JAK2 inhibition significantly reversed F/
P-induced colony formation and promoted EOL-1 cellular
apoptosis. These events were accompanied by dose-dependent
decreases in c-Myc and Survivin expression level. Thus, JAK2 acts
as another crucial intracellular signal protein in F/P-mediated
CEL.
Stats are latent cytoplasmic transcription factors that are
generally considered to be JAKs-dependent, especially in hema-
topoiesis and some hematopoietic diseases. Stat5 was the first Stat
protein to be associated with activation by F/P in CEL, and
subsequent evidence has shown that it is necessary for F/P-
induced colony formation [1,5]. The second Stat molecule to be
identified as a target of F/P was Stat3, and its activation has been
implicated in signal propagation of the F/P protein [27,28].
However, the molecular mechanism by which F/P activates Stat5
and Stat3 remains unclear. The results from our study showed that
JAK2 is involved in the F/P-induced activation of both Stat5 and
Stat3. Phosphorylation of Stat5 was slightly affected(inhibited) by
high concentration of the JAK2 inhibitor, AG490, or JAK2 knock-
down by siRNA. These findings suggest that activation of Stat5 by
F/P may occur to some extent through JAK2, but primarily occurs
Figure 7. JAK2 inhibition blocked IL-5-induced the migration and activation of EOL-1 and PC cells. The EOL-1 or PC cells were treated
with various concentrations of AG490 or transfected with JAK2 siRNA. (A) and (D) Percentage of migrated cell stimulated by IL-5. (B) and (E) EPO
activity was measured by an enzyme-joint spectrophotometer, using the optical density (OD) value at an absorbance of 492 nm. (C) and (F) Cell
degranulation was measured according Strath’s method. Data(mean6SD) representative results derived from three independent experiments.
*P,0.05, compared to untreated group or control siRNA.
doi:10.1371/journal.pone.0034912.g007
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suggest that some activation of Stat5 occurs independently of the
JAK2 [30,31]. Our results also showed that the phosphorylation of
Stat3 was decreased in a dose-dependent manner by JAK2
inhibition. Stat3 has been characterized as a central molecule of
JAK2 intracellular signaling in solid tumor oncogenesis [32]. The
development of eosinophil-associated end-organ infiltration and
damage with release of cytoplasmic toxic mediators are the key
features in CEL patients carrying the F/P gene, and are associated
with poor prognosis due to multiple-organ failure [2,33]. Mouse
models of F/P or IL-5 overexpression revealed that neither
molecule alone is sufficient to induce substantial tissue eosinophil
infiltration or end-organ impairment, but together result in a
severe, rapidly progressive disease resembling CEL [16]. Further-
more, the severity of F/P(+) CEL in humans has been associated
with polymorphic variation at the IL-5 receptor A locus [34]. In
this study, we found that JAK2 was excessively activated by the F/
P in synergism with IL-5 in EOL-1 and PC cells. Thus, we used
IL-5 as a chemoattractant to investigate whether JAK2 is involved
in the chemotaxis of EOL-1 and PC cells in vitro. The results
indicated that JAK2 activation is an important mediator of cell
movement and activation stimulated by IL-5 in vitro. Although the
molecular profile of JAK2 interactions generating signal leading to
cell infiltration and activation remains obscure, our study showed
for the first time that JAK2 maybe an alternative and feasible
target for inhibiting F/P(+) eosinophil-associated tissue infiltration
and dysfunction. The coexistence of T-cell clonality and the F/P
fusion gene in 5%–28% of CEL patients may provide insight into
the complex pathogenesis, but also indicates that IL-5 may be the
most relevant cytokine in the pathogenesis of F/P-mediated CEL
[35,36]. It is rational to consider that JAK2 may be the vital
downstream kinase activated by F/P converged with IL-5-
stimulated intracellular signals in CEL cells [37], and that
excessive phosphorylation of JAK2 may promote higher levels of
eosinophil infiltration and activation in CEL by activating signal
cascades that are different from those in normal eosinophil
biological function.
NF-kB activation has been demonstrated to up-regulate the
ICAM expression of EOL-1 cells, mediating cellular migration
and adhesion [38]. In addition, NF-kB regulates the expression of
key proinflammatory cytokines and other genes in activated
eosinophils. Recent reports have shown that NF-kB is required in
EOL-1 cells for increased expression and constitutive activation of
protein kinase C-delta, which induces cell recruitment and
migration [39,40]. Therefore, the effect of JAK2 on NF-kB
activity was observed in EOL-1 cells in our study, and western blot
results showed that NF-kB activity was decreased in a dose-
dependent manner when JAK2 was inhibited. These results
indicate that NF-kB is another F/P-related signal molecule that
lies downstream of JAK2. Moreover, NF-kB may be one of the
principal mediators of eosinophil cellular infiltration and end-
organ impairment which occur in F/P(+) CEL patients.
Figure 8. JAK2 inhibition resulted in the downregulation of NF-kB, c-Myc and Survivin expression which correlated with Stat3,
PI3K/Akt deactivation. The EOL-1 cells were treated with various concentrations of AG490 or transfected with JAK2 siRNA. Whole-cell lysates were
prepared and subjected to Western blotting or nuclear extracts were probed for phospho-p65 by Western blotting using antibodies to phospho-
specific p65 and PARP. (A) Representative gel images. (B–E) Quantification of A.
doi:10.1371/journal.pone.0034912.g008
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independent proliferation of EOL-1 cells, the colony size of
transduced cells produced by constitutively active Stat5 was
dramatically smaller than those produced by F/P-expressing cells.
These results indicated that additional signaling molecules are a
requisite for the clinical phenotype of F/P(+) CEL. Indeed, both
PI3K and ERK1/2 are excessively activated during F/P-mediated
eosinophil progenitor expansion and abnormal differentiation [5].
Our findings that JAK2 inhibition abated PI3K and Akt activity
suggests that JAK2 can evoke pronounced activation of the PI3K/
Akt signal pathway under conditions of F/P-stimulation. Recent
studies have similarly indicated that activation of the JAK2/PI3K/
Akt signaling pathway can effectively promote cellular prolifera-
tion, thereby contributing to the pathogenesis of hematopoietic
malignancies [30,41]. Moreover, the PI3K/Akt signaling pathway
participates in eosinophil migration and degranulation stimulated
by different chemotaxins [42,43]. It has been suggested that
distinct mechanisms underlie EOL-1 and normal eosinophil
activation [8,40]. In support of this, our results indicated that
the aberrant activation of EOL-1 cells may be due to activation of
the PI3K/Akt signaling pathway and NF-kB induced by the F/P
via JAK2 kinase, but is not solely dependent on the JAKs/Stats
signaling pathway.
In this study, our findings demonstrate that in the EOL-1 cell,
JAK2 is able to control both the activities and gene expression of
several different signaling molecules, including Stat3, PI3K, Akt,
NF-kB, c-Myc and Survivin. This molecular profile is distinctive
between the development and activation of EOL-1 cells and that
of normal eosinophils induced by specific cytokines via the JAKs
pathway (Figure 9). The transcription factors, NF-kB and Stat3,
were previously characterized as critical to various aspects of the
tumorigenic process in a number of malignancies, and shown to be
functioning individually or synergistically. c-Myc is prominent
amongst the target genes of both Stat3 and NF-kB. In contrast, the
anti-apoptosis Survivin gene is promoted by Stat3, but not NF-kB
[44], which is in accordance with the slight contribution of NF-kB
to delayed apoptosis of EOL-1 cells [40].
Our findings reveal that JAK2 is a key target of the F/P fusion
protein and underscores the importance of JAK2 signaling in the
F/P-induced cellular proliferation, survival and infiltration events
that manifest as CEL. JAK2 mediates the F/P-induced expression
of c-Myc and Survivin, possibly through activation of multiple
signaling pathways, particularly Stat3, PI3K/Akt and NF-kB. The
F/P-induced phosphorylation of Stat5 appears to principally occur
through another unknown signalling pathway, as opposed to JAK2
which regulates F/P-induced Stat3. Collectively, this evidences
indicates that the pathogenesis of F/P(+) CEL is correlated with
aberrantly regulated intracellular signaling pathways. Inhibition of
the F/P-induced signal proteins might represent an effective
alternative therapeutic approach. As such, JAK2 inhibition will be
an excellent strategy to manage F/P(+) CEL patients who have
become resistant or intolerant to Imatinib/dasatinib and other
potent tyrosine kinase inhibitors. Moreover, as it is reported that
dual inhibition of JAK2 and Stat5 enhances killing of myelopro-
liferative neoplasia cells [45], JAK2 inhibitors are likely to produce
more benefit when combined with Stat5 inhibitors in the
treatment of F/P(+) CEL. Future studies on the ‘‘cross-talk’’
between the signal molecules involved in F/P(+) CEL will facilitate
a deeper understanding of the pathophysiology of this uniquely
malignant HES/CEL caused by F/P.
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